×

Do you want to link to the other external websites and leave Amgen.com.au?

You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for, and exercises no control over the organisation, views, or accuracy of the information contained on the server or site which you will be accessing. The information you are about to access may not comply with the Australian regulatory environment.

×

Do you want to link to other websites and leave Amgen.com.au?

You are now leaving Amgen Australia’s website. Amgen Australia takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the Australian regulatory environment.

PRODUCT INFORMATION

Refer to approved product information for complete indication.

Aranesp® (darbepoetin alfa)

Aranesp® is used for the treatment of anaemia associated with chronic renal failure, or resulting from concomitantly administered chemotherapy when treating a non-myeloid malignancy.

Aranesp® Product Information

BLINCYTO® (blinatumomab)

BLINCYTO® is indicated for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).

BLINCYTO® Product Information

IMLYGIC (talimogene laherparepvec)

IMLYGIC is an oncolytic immunotherapy derived from recombinantly engineered herpes simplex virus type-1 and is indicated as a monotherapy for the treatment of melanoma in patients with unresectable cutaneous, subcutaneous or nodal lesions after initial surgery.

IMLYGIC Product Information

KYPROLIS® (carfilzomib)

KYPROLIS®, as part of combination therapy with dexamethasone or lenalidomide and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.

KYPROLIS® Product Information

Neulasta® (pegfilgrastim)

A long acting leukocyte growth factor used to decrease the duration of severe neutropenia and so reduce the incidence of infection in patients with cancer.

Neulasta® Product Information

NEUPOGEN® (filgrastim)

A leukocyte growth factor used to decrease the duration of neutropenia and incidence of infection in patients with cancer, and for use in patients with severe chronic neutropenia and HIV patients with neutropenia. It is also used in mobilisation of peripheral blood progenitor cells.

NEUPOGEN® Product Information

Nplate® (romiplostim)

A thrombopoietin mimetic used to treat low blood platelet counts in adults with chronic immune thrombocytopenic purpura (ITP).

Nplate® Product Information

Prolia® (denosumab)

Prolia® is indicated:
  • For the treatment of osteoporosis in postmenopausal women. Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures.
  • As treatment to increase bone mass in men with osteoporosis at increased risk of fracture.
  • As treatment to increase bone mass in men with osteopaenia receiving androgen deprivation therapy for non-metastatic prostate cancer.

Prolia® Product Information

Repatha (evolocumab)

Repatha is indicated in adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease (DVC) in combination with a statin or statin with other lipid lowering therapies, or in combination with other lipid lowering therapies in patients who are statin-intolerant. Repatha is also indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.

Repatha Product Information

Sensipar® (cinacalcet HCl)

Sensipar® is used for the treatment of secondary hyperparathyroidism in dialysis patients with end stage renal disease, hypercalcaemia in patients with parathyroid carcinoma and primary hyperparathyroidism in patients for whom parathyroidectomy is not an option.

Sensipar® Product Information

Vectibix® (panitumumab)

An EGFR inhibitor used to treat patients with wild-type RAS colorectal cancer that has spread to other parts of the body in combination with chemotherapy or after failure of chemotherapy.

Vectibix® Product Information

XGEVA® (denosumab)

XGEVA® is indicated for the prevention of skeletal related events in patients with bone metastases from solid tumours.

XGEVA® Product Information